Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Pörssitiedote

BrainCool appoints Jens Lindberg as new Chairman of the Board

BrainCool
Lataa tiedote

BrainCool AB (publ) today announces that its Board Director Jens Lindberg has been appointed Chairman. He replaces Hans Henriksson, who has expressed his wish to resign from the Board as he approaches the age of 75 years. Hans Henriksson has been engaged in BrainCool since the company’s foundation in 2014. The changes to the Board of Directors take effect immediately.

“It has been an enriching experience being part of BrainCool’s development over the past ten years. After the successful rights issue in May and with three new Board Directors joining in June, BrainCool has entered a new phase. I think this is a suitable time to hand over the responsibility to the new Board as it now has the full grasp of the company. I see continued great potential in the company´s future, which I will closely follow in my role as an investor,” comments Hans Henriksson, BrainCool’s outgoing Chairman of the Board.

Jens Lindberg was elected as a new Board Director of BrainCool at the annual general meeting in June 2024. He has 25 years of international experience in life science and a proven track record in developing and commercializing innovative products. He is currently CEO of Medivir AB, with a previous background as interim CEO and VP of Global Commercial Operations at Sedana Medical AB, as well as from several senior positions at Astra Zeneca plc.

“Since joining the Board of BrainCool in June, I have been able to acquire in-depth knowledge of the company. I am impressed with the level of innovation in the product portfolio and the great engagement of the entire team. We have a solid foundation to take the next step in establishing BrainCool™ System as the preferred option in surface cooling and bringing RhinoChill® to a commercialization phase, all with the aim of improving the lives of patients with stroke and cardiac arrest. In my new role as Chairman of the Board, I look forward to working closely with our CEO, Jon Berg, and the team to ensure continued success. I would also like to take the opportunity to thank Hans Henriksson for his great contributions to BrainCool over the company’s first 10 years,” said Jens Lindberg, BrainCool’s incoming Chairman of the Board.

Jens Lindberg (b. 1971) is considered independent in relation to the company, its management and the company's major shareholders.



Contact
For more information
Jon Berg - CEO
+46 722 50 91 19
E-mail: jon.berg@braincool.se

About Us
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named “BRAIN”.
Eminova Fondkommission AB is the company’s Certified Adviser.

This information is information that BrainCool is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-12-03 15:10 CET.

Attachments
BrainCool appoints Jens Lindberg as new Chairman of the Board

Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.